Prostaglandin F2α Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 06 2020
Historique:
entrez: 6 6 2020
pubmed: 6 6 2020
medline: 2 1 2021
Statut: ppublish

Résumé

To elucidate the molecular etiology of deepening of the upper eyelid sulcus (DUES) induced by prostaglandin (PG) analogs, a three-dimensional (3D) tissue culture system was employed using human orbital fibroblasts (HOFs). During adipogenesis, changes in HOF 3D organoid sizes, as well as their lipids stained by BODIPY and expression of the extracellular matrix (ECM) by immunolabeling and/or quantitative PCR, were studied in the presence or absence of either 100-nM bimatoprost acid or 100-nM prostaglandin F2α. The size of the 3D organoids increased remarkably during adipogenesis, but such increases were significantly inhibited by the presence of PG analogs. Staining intensities by BODIPY and mRNA expression of peroxisome proliferator-activated receptor gamma were significantly increased upon adipogenesis but were not influenced by the presence of PG analogs. Unique changes in ECM expression observed with or without adipogenic differentiation were significantly modified by the presence of PG analogs. Our present study indicates that PG analogs have the potential to modulate the ECM network within HOF 3D organoids. Thus, a 3D tissue culture system may be a suitable strategy for understanding the disease etiology of DUES.

Identifiants

pubmed: 32503053
pii: 2766310
doi: 10.1167/iovs.61.6.13
pmc: PMC7415291
doi:

Substances chimiques

4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 0
Antihypertensive Agents 0
Boron Compounds 0
Fluorescent Dyes 0
PPAR gamma 0
RNA, Messenger 0
Dinoprost B7IN85G1HY
Bimatoprost QXS94885MZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13

Références

Int J Biol Sci. 2014 Jul 25;10(8):825-33
pubmed: 25076859
Surv Ophthalmol. 2008 Nov;53 Suppl1:S39-43
pubmed: 19038623
J Ocul Pharmacol Ther. 2012 Apr;28(2):146-52
pubmed: 22107041
Invest Ophthalmol Vis Sci. 2014 Mar 04;55(3):1269-76
pubmed: 24508785
Lipids Health Dis. 2013 Dec 11;12:182
pubmed: 24325571
Nat Med. 2004 Apr;10(4):355-61
pubmed: 15057233
J Biol Chem. 1988 Nov 5;263(31):16163-9
pubmed: 2460444
Thromb Haemost. 2002 Aug;88(2):345-53
pubmed: 12195710
Endocrinology. 2019 Jan 1;160(1):20-35
pubmed: 30388216
Biol Cell. 2002 Jun;94(3):197-203
pubmed: 12206658
Orbit. 2010 Dec;29(6):357-9
pubmed: 21158579
Nat Med. 2009 Dec;15(12):1360-1
pubmed: 19966771
Mol Vis. 2018 Jul 26;24:509-517
pubmed: 30090014
Nutr Metab (Lond). 2017 Dec 28;14:79
pubmed: 29299041
Am J Ophthalmol. 1998 Oct;126(4):487-97
pubmed: 9780093
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
Trends Cell Biol. 2011 Dec;21(12):745-54
pubmed: 22033488
PLoS One. 2013 Jun 11;8(6):e66017
pubmed: 23776595
Jpn J Ophthalmol. 2011 Jan;55(1):22-7
pubmed: 21331688
Ophthalmology. 2009 Jul;116(7):1243-9
pubmed: 19450880
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5912-5923
pubmed: 30551199
Surv Ophthalmol. 2008 Nov;53 Suppl1:S93-105
pubmed: 19038628
Br J Ophthalmol. 2017 Jun;101(6):130-195
pubmed: 28559477
Mol Biol Cell. 2002 Oct;13(10):3546-59
pubmed: 12388756
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2824-9
pubmed: 18287018
Mol Vis. 2006 Jul 12;12:774-90
pubmed: 16862071
PLoS One. 2013 May 01;8(5):e61638
pubmed: 23650502
Jpn J Ophthalmol. 2011 Nov;55(6):600-4
pubmed: 21953485
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63
pubmed: 16249494
Br J Pharmacol. 2005 Feb;144(4):493-501
pubmed: 15678094
Eye (Lond). 2014 Dec;28(12):1446-51
pubmed: 25233818
Physiol Rev. 1998 Jul;78(3):783-809
pubmed: 9674695
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a004978
pubmed: 21421911
Clin Ophthalmol. 2014 Sep 26;8:1967-85
pubmed: 25328381
Hum Mol Genet. 2017 Aug 1;26(R1):R21-R27
pubmed: 28505344
Nat Med. 2009 Dec;15(12):1426-30
pubmed: 19966781
Clin Ophthalmol. 2013;7:1441-6
pubmed: 23885167
Biophys J. 2016 Jul 12;111(1):50-6
pubmed: 27410733
Cell. 1983 Dec;35(3 Pt 2):657-66
pubmed: 6686086
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
J Glaucoma. 2013 Oct-Nov;22(8):626-31
pubmed: 22936280
Curr Eye Res. 2013 Jan;38(1):70-4
pubmed: 23078159
PLoS One. 2014 Apr 29;9(4):e96249
pubmed: 24781779
Cell. 2006 May 5;125(3):577-91
pubmed: 16678100
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18024-9
pubmed: 15601776
Anat Rec (Hoboken). 2017 Aug;300(8):1371-1390
pubmed: 28187500
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Clin Ophthalmol. 2009;3:663-70
pubmed: 20054414
Optom Vis Sci. 2004 Aug;81(8):574-7
pubmed: 15300114
J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56
pubmed: 15181022
Adipocyte. 2012 Apr 1;1(2):89-95
pubmed: 23700517
Curr Opin Cell Biol. 2002 Oct;14(5):633-9
pubmed: 12231360

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH